ReviewCancer research2015
Antiangiogenic VEGF-Ax: A New Participant in Tumor Angiogenesis.
Review in Cancer research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 66 citations in OpenAlex.
- NOL7 Inhibits Ovarian Cancer Progression and Suppresses Angiogenesis by Stabilizing GADD45A to Deactivate STAT3.Cancer science · 2026Article
- Kisspeptin-10 Prevents the Development of Cerebral Aneurysms by Reducing the Expression of Egr-1.CNS neuroscience & therapeutics · 2025Article
- A Multimodal Energy-Depletion Strategy for Cooperative Tumor Metabolism Regulation in Enhanced Cancer Therapy.Biomaterials research · 2025Article
- Expression of 10 circulating cytokines/chemokines in HBV-related liver disease.Infectious agents and cancer · 2024Article
- Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients.Frontiers in oncology · 2024Article
- Golgi Protein 73 Promotes Angiogenesis in Hepatocellular Carcinoma.Research (Washington, D.C.) · 2024Article
- Seryl-tRNA synthetase promotes translational readthrough by mRNA binding and involvement of the selenocysteine incorporation machinery.Nucleic acids research · 2023Article
- MicroRNA-409-5p Inhibits GIST Tumorigenesis and Improves Imatinib Resistance by Targeting KDM4D Expression.Current medical science · 2023Article
- Acute Myocardial Infarction Due to Coronary Artery Embolism during Chemotherapy with mFOLFOX-6 Plus Bevacizumab for Metastatic Colon Cancer.Internal medicine (Tokyo, Japan) · 2023Article
- NSD1 promotes esophageal cancer tumorigenesis via HIF1α signaling.Cell biology and toxicology · 2023Article
- Single-cell RNA sequencing analysis of shrimp immune cells identifies macrophage-like phagocytes.eLife · 2022Article
- Glycogen synthase kinase GSK3α promotes tumorigenesis by activating HIF1/VEGFA signaling pathway in NSCLC tumor.Cell communication and signaling : CCS · 2022Article
- ATF5 and HIF1α cooperatively activate HIF1 signaling pathway in esophageal cancer.Cell communication and signaling : CCS · 2021Article
- Tanshinone IIA suppresses ovarian cancer growth through inhibiting malignant properties and angiogenesis.Annals of translational medicine · 2020Article
- Apatinib induces 3-hydroxybutyric acid production in the liver of mice by peroxisome proliferator-activated receptor α activation to aid its antitumor effect.Cancer science · 2019Article
- Mammalian Eps15 homology domain 1 potentiates angiogenesis of non-small cell lung cancer by regulating β2AR signaling.Journal of experimental & clinical cancer research : CR · 2019Article
- High expression of SDF-1 and VEGF is associated with poor prognosis in patients with synovial sarcomas.Experimental and therapeutic medicine · 2018Article
- How Ribosomes Translate Cancer.Cancer discovery · 2017Review
- MicroRNA-16-5p overexpression suppresses proliferation and invasion as well as triggers apoptosis by targeting VEGFA expression in breast carcinoma.Oncotarget · 2017Article
- Overexpression of Antiangiogenic Vascular Endothelial Growth Factor Isoform and Splicing Regulatory Factors in Oral, Laryngeal and Pharyngeal Squamous Cell CarcinomasAsian Pacific journal of cancer prevention : APJCP · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 2 countries.
Funding
Abstract
The transcript of the angiogenic factor vascular endothelial growth factor A (VEGF-A) is subject to a multitude of stimulus-dependent, posttranscriptional regulatory events, consistent with its unusually long 3' untranslated region. We have recently reported translational readthrough of VEGFA mRNA whereby translating ribosomes traverse the canonical stop codon to a conserved, downstream stop codon, generating VEGF-Ax ("x" for extended), a novel, extended isoform with an additional 22 amino acids appended at the C-terminus. This event is the first vertebrate example of protein-regulated, programmed translational readthrough that generates a protein with a known function. Remarkably, VEGF-Ax exhibits potent antiangiogenic activity, both in vitro and in vivo, thus raising profound clinical implications, particularly with respect to cancer treatment. In this review, we discuss the potential of VEGF-Ax as a therapeutic agent and drug target, as well as its possible role in the failure of, or resistance to, conventional anti-VEGF therapies in many types of cancers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.